You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The S0 UAS, an Air Deployed Solution for Boundary Layer Observations in Turbulent Environments

    SBC: BLACK SWIFT TECHNOLOGIES LLC            Topic: 8213

    Previous efforts have demonstrated that targeted observations of tropical storms by UAS can provide extremely valuable data sets for improving forecasts and models, but are also difficult to obtain. A number of obstacles including regulations and the distance required to intercept evolving storms have limited the number of land based flights. The use of airborne deployed UAS have recently overcome ...

    SBIR Phase II 2019 Department of CommerceNational Oceanic and Atmospheric Administration
  2. Development of a Solar Powered Aerosol Reference Calibrator

    SBC: Access Sensor Technologies LLC            Topic: 813

    This project will develop and demonstrate an inexpensive and portable calibration system for low-cost aerosol sensors. Current calibration methods are cost prohibitive and lack generalizability from one location (or season) to the next, making them impractical for implementation. Access Sensor Technologies (AST) proposes to improve and validate a solar powered aerosol reference calibrator (SPARC) ...

    SBIR Phase II 2019 Department of CommerceNational Oceanic and Atmospheric Administration
  3. Rapid Point-of-Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood

    SBC: ZYMERON CORP            Topic: NIAID

    TuberculosisTBis currently the leading infectious cause of death worldwideTB treatment includes multiple different combinations of antibioticsdosesand long time periodsThe current standard includes an intensive phase ofmonthsfollowed by a continuation phase of eitherormonthsHowevertreatment outcome can be poor due to drug drug interactionsimpaired medication adherencedrug absorption and metabolism ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Mobile Health Point-of-Care Diagnostics for Tuberculosis

    SBC: B & W TEK INC            Topic: NIAID

    TuberculosisTBkilled an estimatedmillion people in the world inOverof the mortalities associated with this deisease occurred in regions of the world where access to reliable TB testing and other suppotive infrastructure is severely limitedUntil there are pivotal technological innovations in the diagnosis of TB for point of carePOCapplicationthe ambitious goals of the WHO s End TB strategyareductio ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. In Vivo Targeted Degradation of HIV Gag Polyprotein by Gag-PROTAC Reagents

    SBC: ZYMERON CORP            Topic: NIAID

    HIV disease continues to be a serious health issue for the whole worldCurrentlyantiretroviral therapyARTis a widely accepted treatment to HIV infected patientswhich reduces morbidity and mortality and the potential for HIV transmission by suppressing viral replicationHowevertreatment outcomes of ART are limited due to the high adherence requirement and occurrence of drug resistanceProteolysis targ ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: ZYMERON CORP            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. SBIR PHASE 1- TOPIC 394- COMBINATORY TREATMENT MODALITIES UTILIZING RADIATION TO LOCALLY ACTIVATE OR RELEASE SYSTEMICALLY DELIVERED THERAPEUTICS.

    SBC: ZYMERON CORP            Topic: NCI

    Photodynamic therapyPDTutilizes light beam to activate photosensitizers to produce cytotoxic reactive oxygen speciesROSand it has been proposed as a potent treatment to combine with Radiation TherapyRTespecially for the idea of using X ray beam to locally activate PDTXPDTMajority studies about XPDT have used nanoscintillators as the X ray transducer to activate photosensitizersHoweverthe materials ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 382- INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW

    SBC: CELL MICROSYSTEMS INC            Topic: NCI

    Combining both genomic analysis and highEresolution imaging on a cellEbyEcell basis typically relies on customized technology which often requires significant expertise and capital costCell MicrosystemsInchas partnered with Peter SimsPhD of Columbia University to commercialize a novel workflow for integrated imaging and sample preparation for single cell transcriptomic analysisDrSims workflowSingl ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SUVICA INC            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC 389- INTELLIGENT SOFTWARE FOR RADIATION THERAPY PLANNING

    SBC: RADIASOFT LLC            Topic: NCI

    Besides surgeryradiotherapy is the most effective treatment modality for localized prostate cancerThe success of radiotherapy stems from the exploit of a therapeutic window in tumor response and normal tissue tolerance which maximizes the chance of sterilizing the tumor while sparing the surrounding normal tissue from severe damageThis requires an accurate and individualized radiation dose distrib ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government